Kappaproct is a new way of treating ulcerative colitis – phase III data expected by mid- 2014

All patients with severe ulcerative colitis are not helped by the currently available medical therapies. At InDex Pharmaceuticals, we aim to bring new hope to these patients by developing Kappaproct – a first-in-class treatment with potential to alleviate symptoms such as abdominal pain and frequent, bloody diarrhea, and decrease the need for surgical removal of the large intestine.